LeonaBio Q2 net loss widens to $19.0 million; cash falls to $51.1 million
LeonaBio reported a second-quarter 2026 net loss of $19.0 million, or $0.80 per share, up from $7.0 million, or $1.78 per share, a year earlier. The company said higher spending on the Phase 3 ELAINE-3 trial for lasofoxifene drove the increase, and cash, cash equivalents and investments fell to $51.1 million as of June 30, 2026, which shareholders may want to track against the company's funding needs.
Key points
- Net loss was $19.0 million, or $0.80 per share, for the quarter ended June 30, 2026, compared with $7.0 million, or $1.78 per share, a year earlier.
- R&D expenses rose to $12.9 million from $3.7 million, driven mainly by clinical trial spend for the ELAINE-3 trial.
- Cash, cash equivalents and investments were $51.1 million at June 30, 2026, down from $88.3 million at December 31, 2025; net cash used in operations was $37.9 million for the quarter.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.